Global Schizophrenia Drugs Market, Forecast Till 2025

  • Category : Healthcare and Pharma
  • |
  • ID : 794904
  • |
  • Publishe Date : February 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Schizophrenia Drugs Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Increase in number of patients seeking treatment and rising demand for improved healthcare infrastructure are expected to drive the market.

Increase in focus of the governments and health care organizations on mental health and constant investment in research and development. Moreover, rise in incidence of the disease and the increasing need to manage them effectively has led to the growth of the schizophrenia drugs market.

Factors, such as high cost of these drugs and therapies may hinder the growth of the overall market.

Technological advancements such as the development of recombinant Schizophrenia Drugs by market players is further expected to boost the market growth in coming years.

On the basis of product, the market is segmented into Second-Generation, Third-Generation Antipsychotics, Others.

On the basis of Application, the Schizophrenia Drugs market is divided into Oral, Injectables.

Regionally North America region has the largest share in the schizophrenia drugs market. This is attributed to the robust healthcare infrastructure and high rate of adoption of new technology in this region.

Some of the key players operating in this market include Alkermes, Allergan, AstraZeneca, Bristol-Myers Squibb and Company, Eli Lilly, Johnson & Johnson, Pfizer, Sumitomo Dainippon Pharma, and Vanda Pharmaceuticals, among others.

Key Benefits of the Report:
* Global, Regional, Country, Application, and Route of Application Market Size and Forecast from 2014-2025
* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
* Identification of key companies that can influence this market on a global and regional scale
* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
* Detailed insights on emerging regions, Application& Application, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Schizophrenia Drugs providers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity Application, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
* Original Manufacturer,
* Application Supplier,
* Distributors,
* Government Body & Associations, and
* Research Institute
* Pharmacies

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 METHODOLOGY AND MARKET SCOPE
2.1 Research Methodology
2.2 Research Scope & Assumptions

3 SCHIZOPHRENIA DRUGS MARKET — INDUSTRY OUTLOOK
3.1 Market Segmentation and Scope
3.2 Market Size & Growth Prospects
3.3 Schizophrenia Drugs Market — Value Chain / Supply Chain Analysis
3.3.1 Company Landscape
3.4 Schizophrenia Drugs Market — Market Dynamics
3.4.1 Market Driver
3.4.2 Market Restraints
3.4.3 Market Challenges
3.5 Schizophrenia Drugs Market Company Market Share, 2017
3.6 Schizophrenia Drugs Market — Porter\'s Five Forces Analysis
3.7 Schizophrenia Drugs Market — Pestel Analysis

4 SCHIZOPHRENIA DRUGS MARKET Product OUTLOOK
4.1 Schizophrenia Drugs Market Share by product, 2016 & 2025
4.2 Second-Generation,
4.3 Third-Generation Antipsychotics
4.6Others


5 SCHIZOPHRENIA DRUGS MARKET APPLICATION OUTLOOK
5.1 Schizophrenia Drugs Market Share by Application, 2016 & 2025
5.2 Oral
5.3 Injectables

6 SCHIZOPHRENIA DRUGS MARKET REGIONAL OUTLOOK
6.1 Schizophrenia Drugs Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America Schizophrenia Drugs Market, 2014 - 2025
6.2.2 North America Schizophrenia Drugs Market, By Product, 2014 - 2025
6.2.3 North America Schizophrenia Drugs Market, By Application, 2014 - 2025
6.2.5 U.S.
6.2.5.1 U.S. Schizophrenia Drugs Market, By Product, 2014 - 2025
6.2.5.2 U.S. Schizophrenia Drugs Market, By Application, 2014 - 2025
6.2.6 Canada
6.2.6.1 Canada Schizophrenia Drugs Market, By Product, 2014 - 2025
6.2.6.2 Canada Schizophrenia Drugs Market, By Application, 2014 - 2025
6.3 Europe
6.3.1 Europe Schizophrenia Drugs Market, 2014 - 2025
6.3.2 Europe Schizophrenia Drugs Market, By Product, 2014 - 2025
6.3.3 Europe Schizophrenia Drugs Market, By Application, 2014 - 2025
6.3.5 Germany
6.3.5.1 Germany Schizophrenia Drugs Market, By Product, 2014 - 2025
6.3.5.2 Germany Schizophrenia Drugs Market, By Application, 2014 - 2025
6.3.6 UK
6.3.6.1 UK Schizophrenia Drugs Market, By Product, 2014 - 2025
6.3.6.2 UK Schizophrenia Drugs Market, By Application, 2014 - 2025
6.4 Asia Pacific
6.4.1 Asia Pacific Schizophrenia Drugs Market, 2014 - 2025
6.4.2 Asia Pacific Schizophrenia Drugs Market, By Product, 2014 - 2025
6.4.3 Asia Pacific Schizophrenia Drugs Market, By Application, 2014 - 2025
6.4.5 Australia
6.4.5.1 Australia Schizophrenia Drugs Market, By Product, 2014 - 2025
6.4.5.2 Australia Schizophrenia Drugs Market, By Application, 2014 - 2025
6.4.6 New Zealand
6.4.6.1 New Zealand Schizophrenia Drugs Market, By Product, 2014 -
2025
6.4.6.2 New Zealand Schizophrenia Drugs Market, By Application, 2014 -2025
6.4.7 China
6.4.7.1 China Schizophrenia Drugs Market, By Product, 2014 - 2025
6.4.7.2 China Schizophrenia Drugs Market, By Application, 2014 - 2025
6.4.8 India
6.4.8.1 India Schizophrenia Drugs Market, By Product, 2014 - 2025
6.4.8.2 India Schizophrenia Drugs Market, By Application, 2014 - 2025
6.4.9 Japan
6.4.9.1 Japan Schizophrenia Drugs Market, By Product, 2014 - 2025
6.4.9.2 Japan Schizophrenia Drugs Market, By Application, 2014 - 2025
6.5 South America
6.5.1 South America Schizophrenia Drugs Market, 2014 - 2025
6.5.2 South America Schizophrenia Drugs Market, By Product, 2014 - 2025
6.5.3 South America Schizophrenia Drugs Market, By Application, 2014 - 2025
6.5.5 Brazil
6.5.5.1 Brazil Schizophrenia Drugs Market, By Product, 2014 - 2025
6.5.5.2 Brazil Schizophrenia Drugs Market, By Application, 2014 - 2025
6.5.6 Mexico
6.5.6.1 Mexico Schizophrenia Drugs Market, By Product 2014 - 2025
6.5.6.2 Mexico Schizophrenia Drugs Market, By Application, 2014 - 2025
6.6 MEA
6.6.1 MEA Schizophrenia Drugs Market, 2014 - 2025
6.6.2 MEA Schizophrenia Drugs Market, By Product, 2014 - 2025
6.6.3 MEA Schizophrenia Drugs Market, By Application, 2014 - 2025

7 COMPETITIVE LANDSCAPE
7.1 Alkermes
7.1.2 Financial performance
7.1.3 Application benchmarking
7.1.4 Strategic initiatives
7.2 Allergan
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Application benchmarking
7.2.4 Strategic initiatives
7.3 AstraZeneca
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Application benchmarking
7.3.4 Strategic initiatives
7.4 Bristol-Myers Squibb and Company
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Application benchmarking
7.4.4 Strategic initiatives
7.5 Eli Lilly
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Application benchmarking
7.5.4 Strategic initiatives
7.6 Johnson & Johnson
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Application benchmarking
7.6.4 Strategic initiatives
7.7 Pfizer
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Application benchmarking
7.7.4 Strategic initiatives

End of the report
Disclaimer.

Content are not available

Choose License Type